Esperion Therapeutics (ESPR) Convertible Debt (2012 - 2026)

Esperion Therapeutics has reported Convertible Debt for 8 years, with the latest figure at $97.4 million in Q1 2026.

• For the quarter ending Q1 2026, Convertible Debt rose 0.54% year-over-year to $97.4 million; the trailing twelve-month figure through Mar 2026 stood at $97.4 million (up 0.54% YoY), and the FY2025 full-year result was $97.3 million, up 0.53% from the prior year.
• Convertible Debt for Q1 2026 stood at $97.4 million, roughly flat from $97.3 million in the prior quarter.
• The five-year high for Convertible Debt was $262.9 million in Q3 2024, with the low at $96.7 million in Q4 2024.
• Historically, Convertible Debt has averaged $203.0 million across 5 years, with a median of $259.5 million in 2022.
• Annual changes were most pronounced in 2024 — Convertible Debt advanced 0.67% — and 2025, when it sank 63.06%.
• Esperion Therapeutics' Convertible Debt stood at $259.9 million in 2022, then rose by 0.65% to $261.6 million in 2023, then slumped by 63.02% to $96.7 million in 2024, then increased by 0.53% to $97.3 million in 2025, then gained by 0.14% to $97.4 million in 2026.
• The last three Convertible Debt figures came in at $97.4 million (Q1 2026), $97.3 million (Q4 2025), and $97.1 million (Q3 2025), per Business Quant data.